生命科学资讯

Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data

CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

Hospitals could earn more for buying US-made drugs, CMS proposes

Cardiff execs depart as company drops mixed Phase 2 data

UnitedHealth projects lower revenue in 2026 as it resets its business

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma

AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal

Virtual women’s health company Wisp buys TBD Health

Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcere

UK-US biotech investor Epidarex raises $145M for fourth fund

IRA drug pricing petitions pile up at the Supreme Court

Ex-CytoDyn CEO sentenced to 30 months for pump-and-dump scheme

Catalent plans to close Belgium cell therapy site

Sarepta touts three-year Duchenne gene therapy data after patient deaths

Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing

UK medicines agency seized 20M illegal drugs last year, including GLP-1s

Genmab halts enrollment for cancer drug from ProfoundBio buyout

First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and more

Novo's Wegovy pill off to a solid start after just two weeks on market